The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.29313949
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon Cancer. Version 1.2019 Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf Accessed 401, 2019.
   Google Scholar
• Cremolini C, Schirripa M, Antoniotti C, et al. First-line chemotherapy for mCRC-a review and evidence-based algorithm. Nat Rev Clin Oncol. 2015;12(10):607–619. doi:10.1038/nrclinonc.2015.12926215044
   PubMed Web of Science ®Google Scholar
• Vectibix® (Panitumumab). Thousand Oaks, CA: Amgen Inc.; 2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125147s207lbl.pdf. Accessed 116, 2019.
   Google Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Molecular Cell Biol. 2006;7(7):505–516. doi:10.1038/nrm1962
   PubMed Web of Science ®Google Scholar
• Yang BB, Lum P, Chen A, et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet. 2010;49(11):729–740. doi:10.2165/11535970-000000000-0000020923247
   PubMed Web of Science ®Google Scholar
• Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos HP. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009;29(12):5077–5082.20044619
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: american society of clinical oncology provisional clinical opinion update 2015. J Clin Oncol. 2016;34(2):179–185. doi:10.1200/JCO.2015.63.967426438111
   PubMed Web of Science ®Google Scholar
• Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology. J Mol Diagn. 2017;19(2):187–225. doi:10.1016/j.jmoldx.2016.11.00128185757
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–1664. doi:10.1200/JCO.2006.08.162017470858
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–1634. doi:10.1200/JCO.2007.14.711618316791
   PubMed Web of Science ®Google Scholar
• Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15(6):569–579. doi:10.1016/S1470-2045(14)70118-424739896
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706–4713. doi:10.1200/JCO.2009.27.605520921462
   PubMed Web of Science ®Google Scholar
• Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res. 2015;21(24):5469–5479. doi:10.1158/1078-0432.CCR-15-052626341920
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–4705. doi:10.1200/JCO.2009.27.486020921465
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346–1355. doi:10.1093/annonc/mdu14124718886
   PubMed Web of Science ®Google Scholar
• Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852–864. doi:10.3109/0284186X.2014.89503624666267
   PubMed Web of Science ®Google Scholar
• Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–1034. doi:10.1056/NEJMoa130527524024839
   PubMed Web of Science ®Google Scholar
• Karthaus M, Hofheinz RD, Mineur L, et al. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer. 2016;115(10):1215–1222. doi:10.1038/bjc.2016.34327764839
   PubMed Web of Science ®Google Scholar
• Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013;19(7):1902–1912. doi:10.1158/1078-0432.CCR-12-191323325582
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13–21. doi:10.1093/annonc/mdu37825115304
   PubMed Web of Science ®Google Scholar
• Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888–1894. doi:10.1038/bjc.2015.17325989278
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587–594. doi:10.1016/j.ejca.2015.01.05425673558
   PubMed Web of Science ®Google Scholar
• van Brummelen EMJ, de Boer A, Beijnen JH, Schellens JHM. BRAF mutations as predictive biomarker for response to anti-EGFR monoclonal antibodies. Oncologist. 2017. doi:10.1634/theoncologist.2017-0031
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–2247. doi:10.1200/JCO.2013.53.247324687833
   PubMed Web of Science ®Google Scholar
• Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis. 2017;32(8):1179–1190. doi:10.1007/s00384-017-2800-128424871
   PubMed Web of Science ®Google Scholar
• Peeters M, Forget F, Karthaus M, et al. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. ESMO Open. 2018;3(2):e00297. doi:10.1136/esmoopen-2017-0029729531837
   PubMed Web of Science ®Google Scholar
• Carrato A, Abad A, Massuti B, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017;81:191–202. doi:10.1016/j.ejca.2017.04.02428633089
   PubMed Web of Science ®Google Scholar
• Taieb J, Rivera F, Siena S, et al. Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. J Cancer Res Clin Oncol. 2018;144(2):321–335. doi:10.1007/s00432-017-2534-z29080924
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Montagut C, Wainberg ZA, et al. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 2018;3(4):e000353. doi:10.1136/esmoopen-2018-00035329765773
   PubMed Web of Science ®Google Scholar
• Cremolini C, Rossini D, Dell’Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. Epub 2018 Nov 21.
   PubMed Web of Science ®Google Scholar
• Mauri G, Pizzutilo EG, Amatu A, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019;73:41–53. doi:10.1016/j.ctrv.2018.12.00630616224
   PubMed Web of Science ®Google Scholar
• Fornaro L, Lonardi S, Masi G, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013;24(8):2062–2067. doi:10.1093/annonc/mdt16523666916
   PubMed Web of Science ®Google Scholar
• Bendell JC, Zakari A, Peyton JD, et al. A phase II study of FOLFOXIRI plus panitumumab followed by evaluation for resection in patients with metastatic KRAS wild-type colorectal cancer with liver metastases only. Oncologist. 2016;21(3):279–280. doi:10.1634/theoncologist.2015-043926911408
   PubMed Web of Science ®Google Scholar
• Geissler M, Klingler T, Martens UM, et al. 453PD1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109). Ann Oncol. 2018;29(suppl_8). doi:10.1093/annonc/mdx807
   Google Scholar
• Modest DP, Rivera F, Bachet JB, et al. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: a retrospective analysis of two randomised trials. Int J Cancer. 2019. doi:10.1002/ijc.32110
   Web of Science ®Google Scholar
• Pietrantonio F, Morano F, Corallo S, et al. First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus pan or single-agent pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): the VALENTINO study. J Clin Oncol. 2018;36(15_suppl):3505. doi:10.1200/JCO.2018.36.15_suppl.3505
   Google Scholar
• Nakamura M, Munemoto Y, Takahashi M, et al. SAPPHIRE: a randomized phase II study of mFOLFOX6+ panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6+ panitumumab in patients with colorectal cancer. J Clin Oncol. 2018;36(4_suppl):729. doi:10.1200/JCO.2018.36.4_suppl.729
   Web of Science ®Google Scholar
• Peeters M. Outcome according to Left Vs. Right Side in the Panitumumab Studies. Presented At: ESMO 2016 Congress, Special Session. Copenhagen, Denmark; October 7–11, 2016.
   Google Scholar
• Boeckx N, Koukakis R, de Beeck KO, et al. Effect of primary tumor location on second- or later-line treatment outcomes in patients with RAS wild-type metastatic colorectal cancer and all treatment lines in patients with RAS mutations in four randomized panitumumab studies. Clin Colorectal Cancer. 2018;17(3):170–178.e173. doi:10.1016/j.clcc.2018.03.00529627309
   PubMed Web of Science ®Google Scholar
• Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201. doi:10.1001/jamaoncol.2016.379727722750
   PubMed Web of Science ®Google Scholar
• Peeters M, Price T, Taieb J, et al. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018;119(3):303–312. doi:10.1038/s41416-018-0165-z30013091
   PubMed Web of Science ®Google Scholar
• Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98. doi:10.1016/j.ejca.2016.10.00727907852
   PubMed Web of Science ®Google Scholar
• Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Ann Oncol. 2017. doi:10.1093/annonc/mdx175
   Google Scholar
• Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69–80. doi:10.1016/j.ejca.2017.07.01628787661
   PubMed Web of Science ®Google Scholar
• Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park). 2007;21(11 Suppl 5):34–36.18154217
   PubMedGoogle Scholar
• Kohne CH, Hofheinz R, Mineur L, et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138(1):65–72. doi:10.1007/s00432-011-1061-621960318
   PubMed Web of Science ®Google Scholar
• Thaler J, Karthaus M, Mineur L, et al. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer. 2012;12:438. doi:10.1186/1471-2407-12-43823020584
   PubMed Web of Science ®Google Scholar
• Siena S, Tabernero J, Bodoky G, et al. Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. ESMO Open. 2016;1(2):e000041. doi:10.1136/esmoopen-2016-00004127843597
   PubMedGoogle Scholar
• Bennett L, Zhao Z, Barber B, et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer. 2011;105(10):1495–1502. doi:10.1038/bjc.2011.40921989186
   PubMed Web of Science ®Google Scholar
• Odom D, Barber B, Bennett L, et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011;26(2):173–181. doi:10.1007/s00384-010-1112-521190026
   PubMed Web of Science ®Google Scholar
• Vectibix. INN-panitumumab. Available from: https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf Accessed 331, 2019.
   Google Scholar
• Mitchell EP, Piperdi B, Lacouture ME, et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer. 2011;10(4):333–339. doi:10.1016/j.clcc.2011.06.00422000810
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–1357. doi:10.1200/JCO.2008.21.782820142600
   PubMed Web of Science ®Google Scholar
• Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009;115(7):1544–1554. doi:10.1002/cncr.2408819189371
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. Clin Colorectal Cancer. 2018;17(2):85–96. doi:10.1016/j.clcc.2017.12.00429576427
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Komatsu Y, Yuki S, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol. 2015;11(4):617–627. doi:10.2217/fon.14.25125686117
   PubMed Web of Science ®Google Scholar
• Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol. 2010;17(Suppl 1):S18–S30. doi:10.3747/co.v17is1.615
   PubMed Web of Science ®Google Scholar
• Costa A, Tejpar S, Prenen H, Van Cutsem E. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Target Oncol. 2011;6(4):227–233. doi:10.1007/s11523-011-0200-y22113391
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Galluzzo S, Santini D, et al. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol. 2011;22(5):1141–1146. doi:10.1093/annonc/mdq55021115601
   PubMed Web of Science ®Google Scholar
• Sastre J, Massuti B, Pulido G, et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish cooperative group for the treatment of digestive tumours. Eur J Cancer. 2015;51(11):1371–1380. doi:10.1016/j.ejca.2015.04.01325963019
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Cremolini C, Aprile G, et al. Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope. Oncologist. 2015;20(11):1261–1265. doi:10.1634/theoncologist.2015-017126446234
   PubMed Web of Science ®Google Scholar
• Douillard J, Siena S, Peeters M, Koukakis R, Terwey J, Tabernero J. 547pimpact of baseline age on efficacy and safety of first-line panitumumab (PMAB) + folfox4 vs folfox4 treatment. Ann Oncol. 2014;25(suppl_4):iv187–iv187. doi:10.1093/annonc/mdu333.49
   Google Scholar
• Asimakopoulou N, Souglakos J, Kentepozidis N, et al. Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). J Geriatr Oncol. 2019;10(1):143–148. doi:10.1016/j.jgo.2018.08.00230366852
   PubMed Web of Science ®Google Scholar
• Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–267. doi:10.1038/nature1496926416732
   PubMed Web of Science ®Google Scholar
• Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–523. doi:10.1158/2159-8290.CD-11-010922586653
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–746. doi:10.1016/S1470-2045(16)00150-927108243
   PubMed Web of Science ®Google Scholar
• Townsend A, Tebbutt N, Karapetis C, et al. Phase IB/II study of second-line therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer. Clin Cancer Res. 2018;24(16):3838–3844. doi:10.1158/1078-0432.CCR-17-359029739790
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Andre T, Atreya CE, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 2018;8(4):428–443. doi:10.1158/2159-8290.CD-17-122629431699
   PubMed Web of Science ®Google Scholar
• Cremolini C, Morano F, Moretto M, et al. Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): a case-control study. J Clin Oncol. 2017;35(suppl; abstr 11508). doi:10.1200/JCO.2017.35.15_suppl.11508
   Google Scholar
• Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4(11):1269–1280. doi:10.1158/2159-8290.CD-14-046225293556
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra224. doi:10.1126/scitranslmed.3007094
   Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795–801. doi:10.1038/nm.387026030179
   PubMed Web of Science ®Google Scholar
• Morelli MP, Overman MJ, Dasari A, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26(4):731–736. doi:10.1093/annonc/mdv00525628445
   PubMed Web of Science ®Google Scholar
• Parseghian CM, Loree JM, Morris VK, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243–249. doi:10.1093/annonc/mdy50930462160
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Siena S, Bardelli A, et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol. 2017;29(1):119–126.
   Web of Science ®Google Scholar
• Peeters M, Price T, Boedigheimer M, et al. Evaluation of emergent mutations in circulating cell-free DNA and clinical outcomes in patients with metastatic colorectal cancer treated with panitumumab in the ASPECCT study. Clin Cancer Res. 2019;25(4):1216–1225. doi:10.1158/1078-0432.CCR-18-207230487126
   PubMed Web of Science ®Google Scholar
• Kim TW, Peeters M, Thomas A, et al. Impact of emergent circulating tumor DNA RAS mutation in panitumumab-treated chemoresistant metastatic colorectal cancer. Clin Cancer Res. 2018;24(22):5602–5609. doi:10.1158/1078-0432.CCR-17-337729898991
   PubMed Web of Science ®Google Scholar
• Santos C, Azuara D, Vieitez JM, et al. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Ann Oncol. 2019;30(5):796–803. doi:10.1093/annonc/mdz08230840064
   PubMed Web of Science ®Google Scholar
• Kim TW, Elme A, Kusic Z, et al. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer. 2016;115(10):1206–1214. doi:10.1038/bjc.2016.30927736842
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {±} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(1):107–116. doi:10.1093/annonc/mdt52324356622
   PubMed Web of Science ®Google Scholar
• Hecht JR, Cohn A, Dakhil S, et al. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer. 2015;14(2):72–80. doi:10.1016/j.clcc.2014.12.00925982297
   PubMed Web of Science ®Google Scholar